BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38186580)

  • 21. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Guo B; Wang Y; Liu W; Zhang S
    Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma.
    Jiang Y; Zhang C; Zhang J; Han D; Shi X
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108344. PubMed ID: 34763233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TREM2 as a Potential Immune-Related Biomarker of Prognosis in Patients with Skin Cutaneous Melanoma Microenvironment.
    Zhu X; Zeng Z; Chen M; Chen X; Hu D; Jiang W; Du M; Chen T; Chen T; Liao W; Zhang C; Qu Y; Pan W
    Dis Markers; 2023; 2023():8101837. PubMed ID: 36741909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
    Song J; Yang R; Wei R; Du Y; He P; Liu X
    Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM.
    Zhang W; Xie X; Huang Z; Zhong X; Liu Y; Cheong KL; Zhou J; Tang S
    Front Immunol; 2022; 13():919145. PubMed ID: 36211371
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Huang Y; Lin A; Gu T; Hou S; Yao J; Luo P; Zhang J
    Immunotherapy; 2023 Oct; 15(15):1275-1291. PubMed ID: 37584225
    [No Abstract]   [Full Text] [Related]  

  • 27. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
    Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
    Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression profile and prognostic values of LSM family in skin cutaneous melanoma.
    Sun X; Zhang J; Xiao C; Ge Z
    BMC Med Genomics; 2022 Nov; 15(1):238. PubMed ID: 36371223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma.
    Wu S; Liang Y; Zang Q; Xing Z; Yin P; Sun R; Dai B
    Appl Bionics Biomech; 2022; 2022():5160748. PubMed ID: 35607429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanoma.
    Yang H; Che D; Gu Y; Cao D
    Front Genet; 2022; 13():940306. PubMed ID: 36110204
    [No Abstract]   [Full Text] [Related]  

  • 31. FAT10 is a Prognostic Biomarker and Correlated With Immune Infiltrates in Skin Cutaneous Melanoma.
    Wang Y; Zhang H
    Front Mol Biosci; 2022; 9():805887. PubMed ID: 35300113
    [No Abstract]   [Full Text] [Related]  

  • 32. CEBPB is associated with active tumor immune environment and favorable prognosis of metastatic skin cutaneous melanoma.
    Yang J; Xu Y; Xie K; Gao L; Zhong W; Liu X
    Front Immunol; 2022; 13():991797. PubMed ID: 36353635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma.
    He S; Ding Y; Ji Z; Yuan B; Chen J; Ren W
    Cancer Cell Int; 2023 Jun; 23(1):122. PubMed ID: 37344870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined signature of G protein-coupled receptors and tumor microenvironment provides a prognostic and therapeutic biomarker for skin cutaneous melanoma.
    Song B; Wang K; Peng Y; Zhu Y; Cui Z; Chen L; Yu Z; Song B
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18135-18160. PubMed ID: 38006451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unveiling the link between inflammasomes and skin cutaneous melanoma: Insights into expression patterns and immunotherapy response prediction.
    Sheng Y; Liu J; Zhang M; Zheng S
    Math Biosci Eng; 2023 Nov; 20(11):19912-19928. PubMed ID: 38052629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of the paired box gene 3 inhibits the progression of skin cutaneous melanoma by inhibiting c-MET tyrosine kinase : PAX3 downregulation inhibits melanoma progression.
    Zhang K; Yu C; Tian R; Zhang W; Tang S; Wang G
    Mol Biol Rep; 2022 Oct; 49(10):9137-9145. PubMed ID: 36057879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis.
    Zeng S; Xu Z; Liang Q; Thakur A; Liu Y; Zhou S; Yan Y
    Chem Biol Interact; 2023 Mar; 373():110372. PubMed ID: 36736488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A CD8
    Sun S; Zhi Z; Su Y; Sun J; Li Q
    Front Immunol; 2022; 13():1039565. PubMed ID: 36341357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis.
    He Y; Wang X
    Comput Biol Med; 2023 Dec; 167():107591. PubMed ID: 37875043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.